Molecular pathology of colorectal cancer].

Christine Woischke, Marlies Michl, Jens Neumann

Pathologie (Heidelberg, Germany) 2023 Sep

filter terms:

In recent years, the treatment of colorectal carcinoma has experienced increasing individualization. In addition to RAS and BRAF mutational status that is firmly established in routine diagnostics, new therapeutic options evolved based on MSI and HER2 status as well as primary tumour localization. Offering the best targeted options in therapy requires new evidence-based decision-making algorithms regarding timing and scope of molecular pathological diagnostics in order for patients to receive an optimized therapy according to current treatment guidelines. New targeted therapies, some of which are about to be approved and for which pathology has to provide new molecular pathological biomarkers, will also play an increasingly important role in the future. © 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Citation

Christine Woischke, Marlies Michl, Jens Neumann. Molecular pathology of colorectal cancer]. Pathologie (Heidelberg, Germany). 2023 Sep;44(5):279-286